DNDi and its partner Epichem are pleased to announce that the Australian Tropical Medicine Commercialisation Grants Programme (ATMCG), with the support of Australia’s Trade and Investment Ministry (AusTrade), are providing $250,000 for a project which is focused on developing new treatments for leishmaniasis. The name of the project is: “Novel compounds for the treatment of Leishmaniasis in humans and animals,” which will be led by PharmAust Limited’s (ASX:PAA) subsidiary Epichem, in partnership with DNDi.
DNDi will work in collaboration with Epichem who will provide the synthetic and medicinal chemistry component of this research programme.
Twelve applications to the ATMCG programme have been successful: four from Victoria, four from Queensland, two from New South Wales and two from Western Australia. Five of the successful applicants are private companies, two are independent research institutes and five are from Australian universities.